Company logo

VINC - Vincerx Pharma, Inc.

NASDAQ -> Healthcare -> Biotechnology
Palo Alto, United States
Type: Equity

VINC price evolution
VINC
(in millions $) 30 Oct 2024 30 Jun 2024 31 Mar 2024 31 Dec 2023
Current assets
Cash $8.01 $5.19 $12.85
Short term investments $8.4
Net receivables $1.06 $2.35 $2.23 $1.04
Inventory
Total current assets $11.75 $18.28 $7.68 $14.73
Long term investments
Property, plant & equipment $1.52 $1.79 $2.06 $2.33
Goodwill & intangible assets
Total noncurrent assets $3.24 $3.41 $3.48
Total investments $8.4
Total assets $14.95 $21.53 $11.08 $18.22
Current liabilities
Accounts payable $1.96 $1.54 $2.31 $2.5
Deferred revenue
Short long term debt $1.24 $1.2 $1.16
Total current liabilities $5.42 $5.33 $10.63 $5.61
Long term debt $0.7 $1.02 $1.34
Total noncurrent liabilities $0.75 $1.07 $1.39
Total debt $1.93 $2.22 $2.5
Total liabilities $5.84 $6.08 $11.71 $7
Shareholders' equity
Retained earnings -$181.19 -$173.35 -$171.54 -$159.11
Other shareholder equity $0.1 $0.02 $0.06 $0.01
Total shareholder equity $15.45 -$0.62 $11.22
(in millions $) 31 Dec 2023 31 Jan 2023 31 Dec 2021 31 Dec 2020
Current assets
Cash $12.85 $11.73 $111.56 $61.79
Short term investments $40.8
Net receivables $1.04 $1.37
Inventory
Total current assets $14.73 $55.96 $111.84 $63.11
Long term investments
Property, plant & equipment $2.33 $3.24 $4.18
Goodwill & intangible assets
Total noncurrent assets $3.48 $3.32 $5.83 $0.08
Total investments $40.8
Total assets $18.22 $59.29 $117.68 $63.19
Current liabilities
Accounts payable $2.5 $3.06 $2.02 $5.5
Deferred revenue
Short long term debt $1.16 $1.02 $0.74
Total current liabilities $5.61 $9.16 $13.92 $37.81
Long term debt $1.34 $2.41 $3.44
Total noncurrent liabilities $1.39 $2.46 $3.44
Total debt $2.5 $3.44 $4.17
Total liabilities $7 $11.62 $17.36 $37.81
Shareholders' equity
Retained earnings -$159.11 -$121.34 -$55.97 -$16.66
Other shareholder equity $0.01 -$0.03 -$0.02
Total shareholder equity $11.22 $47.67 $100.32 $25.38
(in millions $) 30 Oct 2024 30 Jun 2024 31 Mar 2024 31 Dec 2023
Revenue
Total revenue
Cost of revenue
Gross Profit
Operating activities
Research & development $3.75 $4.56 $3.71
Selling, general & administrative $3.61 $2.92 $1.82
Total operating expenses $7.37 $7.48 $5.53
Operating income -$7.37 -$7.48 -$5.53
Income from continuing operations
EBIT -$1.81 -$12.43 -$4.95
Income tax expense
Interest expense
Net income
Net income -$1.81 -$12.43 -$4.95
Income (for common shares) -$1.81 -$12.43 -$4.95
(in millions $) 31 Dec 2023 31 Dec 2022 31 Dec 2021 31 Dec 2020
Revenue
Total revenue
Cost of revenue
Gross Profit
Operating activities
Research & development $28.97 $52.15 $40.08 $7.12
Selling, general & administrative $13.64 $18.95 $22.57 $3.6
Total operating expenses $42.61 $73.57 $62.66 $10.71
Operating income -$42.61 -$73.57 -$62.66 -$10.71
Income from continuing operations
EBIT -$40.16 -$65.37 -$39.31 -$16.61
Income tax expense
Interest expense $0.01
Net income
Net income -$40.16 -$65.37 -$39.31 -$16.62
Income (for common shares) -$40.16 -$65.37 -$39.31 -$16.62
(in millions $) 30 Oct 2024 30 Jun 2024 31 Mar 2024 31 Dec 2023
Net income -$1.81 -$12.43 -$4.95
Operating activities
Depreciation $0.27 $0.26 $0.26
Business acquisitions & disposals
Stock-based compensation $0.91 $0.53 $0.46
Total cash flows from operations -$5.83 -$7.74 -$8.02
Investing activities
Capital expenditures
Investments -$8.34 $5.75
Total cash flows from investing -$6.96 -$8.34 $5.75
Financing activities
Dividends paid
Sale and purchase of stock $17 $0.01 $0.02
Net borrowings
Total cash flows from financing $17.01 $17 $0.01 $0.02
Effect of exchange rate $0.07 -$0.02 $0.07 -$0.04
Change in cash and equivalents -$9.83 $2.81 -$7.66 -$2.29
(in millions $) 31 Dec 2023 31 Dec 2022 31 Dec 2021 31 Dec 2020
Net income -$40.16 -$65.37 -$39.31 -$16.62
Operating activities
Depreciation $0.92 $0.94 $0.34
Business acquisitions & disposals
Stock-based compensation $3.56 $12.44 $23.31 $4.38
Total cash flows from operations -$40.45 -$59.6 -$33.4 -$2.28
Investing activities
Capital expenditures -$5.26
Investments $41.5 -$40.58
Total cash flows from investing $41.5 -$40.58 -$5.26
Financing activities
Dividends paid
Sale and purchase of stock $0.11 $0.28 $88.45 $64.07
Net borrowings
Total cash flows from financing $0.11 $0.28 $88.45 $64.07
Effect of exchange rate -$0.04 $0.07 -$0.02
Change in cash and equivalents $1.12 -$99.83 $49.77 $61.79
Fundamentals
Market cap $40.81M
Enterprise value N/A
Shares outstanding 31.40M
Revenue N/A
EBITDA N/A
EBIT N/A
Net Income N/A
Revenue Q/Q N/A
Revenue Y/Y N/A
P/E ratio N/A
EV/Sales N/A
EV/EBITDA N/A
EV/EBIT N/A
P/S ratio N/A
P/B ratio N/A
Book/Share N/A
Cash/Share N/A
EPS N/A
ROA N/A
ROE N/A
Debt/Equity 0.62
Net debt/EBITDA N/A
Current ratio 2.17
Quick ratio N/A